Mortality risk in intravenous drug users in Bologna and its determining factors. Results of a longitudinal study;La mortalità dei tossicodipendenti nella città di Bologna e i suoi determinanti. Risultati di uno studio longitudinale

Epidemiologia e Prevenzione

Volumn 32, Issue 2, 2008, Pages 99-107

  Pavarin, Raimondo Maria ^a  

^a ASL di Bologna   (Italy)

Author keywords

AIDS; Heroin; Longitudinal study; Mortality; Overdose

Indexed keywords

ADULT; ARTICLE; FEMALE; HUMAN; ITALY; LONGITUDINAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; SUBSTANCE ABUSE;

ADULT; FEMALE; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 54449085875     PISSN: 11209763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ciccolallo L, Morandi G, Pavarin R, Sorio C, Buiatti E. La mortalità dei tossicodipendenti nella regione Emilia Romagna e i suoi determinanti. Risultati di uno studio longitudinale, Epidemiol Prev 2000;24(2):75-80.
2. Sabbatani S, Di Crescenzo E, Giorni L, Giordano I. Tasso di mortalità correlato all'Aids e ad altre cause nei tossicodipendenti. Infez Med 1996;4(2):93-99.
3. Pavarin R, Prata L. Studio longitudinale sulla mortalità dei tossicodipendenti a Bologna e i suoi determinanti. OdV 2001;28(3):17-24.
4. Antolini G, Pirani M., Morandi G, Sorio C. Differenze di genere e mortalità in una coorte di eroinomani nelle province emiliane Di Modena e Ferrara, 1975-1999. Epidemiol Prev 2006;30(2):124-32.
5. Gruppo Esedra, Mortalità tra i tossicodipendenti: studio multicentrico italiano. Epidemiol Prev 1997;21(4):256-71.
6. Cipriani F, Abbate B, Ameglio M et al. Epidemiologia della tossicodipendenza in Toscana. I risultati dello studio "Micotox" sulla mortalità per tune le cause e sull'incidenza dei tumori in una coorte di eroinomani Toscani nel periodo 1985-1994. Salutee territorio 1998;111:329-35.
7. Bargagli AM, Sperati A, Davoli M, Forestiere F, Perucci CA. Mortalità among problem drug users in Rome: an 18-year follow-up study, 1980-97. Addiction 2001;96(10):1455-63.
8. Galli M, Musicco M. Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection COMCAT Study group. AIDS 1994;8(10):1457-63.
9. Mezzelani P, Quaglio GL, Venturini L, Lugoboni F, Friedman SR, Des Jarlais DC. A Multicentre study on the causes of death among Italian injecting drug users. Aids has overtaken overdose as the principal cause of death. AIDS Care 1998;10(1):61-67.
10. Quaglio G., Talamini G, Lechi A, Venturini L, Lugoboni F, Mezzelani P; Gruppo Intersert di Collaborazione Scientifica (GICS). Study of 2708 heroin related deaths in north-eastern Italy 1985-98 to stablish the main causes of death. Addiction 2001;96(8):1127-37.
11. Rocchi MB, Miotto P, Preti A. Distribution of deaths by unintentional illicit drug overdose in Italy based on periodicity over time, 1984-2000. Drug Alcohol Depend 2005;72(1):23-31.
12. Preti A, Miotto, De Coppi M. Deaths by unintentional illicit drug overdose in Italy, 1984-2000. Drug Alcohol Depend 2000;66(3):275-82.
13. Goedert JJ, Pizza G, Gritti FM et al. Mortality among drug users in the AIDS Era. Int J Epidemiol 1995;24(6):1204-10.
14. Zaccarelli M, Gattari P, Rezza G et al. Impact of HIV Infection on non-AIDS mortalità among Italian injecting drug users, AIDS 1994;8(3):345-50.
15. Bargagli AM, Hickman M, Davoli M et al., COSMO European Group. Drug related mortality and its impact on adult mortality in European countries. Eur J Public Health 2006;16(2):198-202.
16. Ciminale M, Lemma P, Faggiano F. Differenze di genere negli esiti della tossicodipendenza a Torino. Epidemiol Prev 1996;20(2-3):267-68.
17. Costa G, Perucci CA, Dirindin N. Le disuguaglianze nella Salute e il piano sanitario. Epidemiol Prev 1999;23(3):133-40.
18. Cardano M, Costa G, Demaria M, Merler E, Biggeri A. Le diseguaglianze di mortalità negli studi longitudinali italiani. Epidemiol Prev 1999;23(3):141-52.
19. Merler E, Benvenuti A, Baldi P et al. Condizione socio economica e disuguaglianze nella mortalità nello studio longitudinale toscano (SLTo): persistenza ed evoluzione nel tempo (mortalità generale, tumore del polmone, cirrosi epatica) e aspetti emergenti (Aids e overdose). Epidemiol Prev 1999;23(3):207-14.
20. Puigpinos R, Borrell C, Pasarin MI et al. Inequalities in mortality by social class in men in Barcellona, Spain. Eur J Epidemiol 2000;16(8):751-56.
21. Galea S, Ahren J, Tardiff K et al. Racial-Ethnic disparities in overdose mortalità trends in New York city, 1990-1998. J Urban Health 2003;80(2):201-11.
22. Clayton D, Hills M. Statistical models in Epidemiology. New York, Oxford University Press, 1993, pp. 48-52.
23. Clayton D, Hills M. Statistical models in Epidemiology. New York, Oxford University Press, 1993, pp. 227-29.
24. Selvin S. Statistical analysis of epidemiologic data. New York, Oxford University Press, 2003, pp. 263-76.
25. Rehm J, Frick U, Hatwig C, Gutzwiller F, Geschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994-2000. Drug Alcohol Depend 2005;79(2):137-43.
26. Ward J, Mattick RP, Hall W. The effectiveness of methadone maintenance treatment: an overview. Drug Alcohol Rev 1994;13(3):327-35.
27. Stewart D, Gossop M, Marsden J. Reduction in non-fatal overdose after drug misuse treatment: results from the National Treatment outcome Research Study (HTORS). J Subst Abuse Treat 2002;22(1):1-9.
28. Langendam MW, Van Brussel GH, Coutinho RA, Van Ameijden EJ. The impact of harm-reduction-based metadone treatment on mortality among heroin users. Am J Public Health 2001;91(5):774-80.
29. Schifano P, Bargagli AM, Belleudi V et al. Metadone treatment in clinical practice in Italy: need for improvement. Eur Addict Res 2006;12(3):121-27.
30. Bargagli AM, Schifano P, Davoli M, Faggiano F, Perucci CA. Determinants of metadone treatment assignment among heroin addicts on first admission to public treatment centres in Italy. Drug Alcohol Depend 2005;79(2):191-99.
31. Mawell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas:1994-2002. Drug Alcohol Depend 2005;78(1):73-81.
32. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005;100(6):820-28.
33. Termorshuizen F, Krol A, Prins M, Van Amejjden E J C. Long-term outcome ofchronic drug use. Am J Epidemiol 2005;161(2):271-79.
34. Bennet GA, Higgins DS. Accidental overdose among injecting drug users in Dorset, UK. Addiction 1999;94(8):1179-89.
35. O'Driscoll PT, McGough J, Hagan H et al. Predictors of accidental fatal drug overdose among a cohort of injecting drug users. Am J Public Health 2001;91(6):984-87.
36. Cullen W, Bury G, Langton D. Experience of heroin overdose among drug users attending general practice. Br J Gen Pract 2000;50(456):54649.
37. McGregor C, Darke S, Ali R, Christie P. Experience of non fatal overdose among heroin users in Adelaide, Australia: circumstances and risks perceptions. Addiction 1998;93(5):701-11.
38. Tagliato F, De Battisti Z, Smith FP, Marigo M. Death from heroin overdose: findings from hair analisys. Lancet 1998;351(9120):1923-25.
39. Davoli M, Perucci CA, Forastiere F et al. Risk factors overdose mortality: a case-control study within a cohort of intravenous drug users. Int J Epidemiol 1993;22(2):273-77.
40. Powis B, Strang J, Griffiths P et al. Self reported overdose among injecting drug users in London: extent and nature of the problem. Addiction 1999:94(4):1179-90.
41. Seaman SR, Bretde RP, Gore SM. Mortality from overdose among injecting drug users recendy released from prison: database linkage study. BMJ (International edition) 1998, 316(7129):426-28.
42. Van Haastrecht HJ, Mientjes GH, Van Den Hoek AJ, Coutinho RA. Death from suicide and overdose among drug injectors after disclosure of first HIV test result. AIDS 1994;8(12):1721-25.
43. Rossow I, Lauritzen G. Balancing of the edge of death: suicide attempts and life-threatening overdoses among drug addicts. Addiction 1994;94(2):209-19.